Co-Authors
This is a "connection" page, showing publications co-authored by RAJYALAKSHMI LUTHRA and SRDAN VERSTOVSEK.
Connection Strength
1.265
-
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 2017 08 31; 130(9):1125-1131.
Score: 0.156
-
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015 Aug 06; 126(6):790-7.
Score: 0.136
-
JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms. Blood. 2013 Nov 28; 122(23):3784-6.
Score: 0.120
-
TP53 mutation is rare in primary myelofibrosis. Leuk Lymphoma. 2013 Jul; 54(7):1552.
Score: 0.114
-
Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res. 2009 Jan 01; 15(1):368-73.
Score: 0.087
-
Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol. 2022 11; 35(11):1677-1683.
Score: 0.055
-
Long-term results of frontline dasatinib in chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1502-1511.
Score: 0.047
-
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674.
Score: 0.042
-
A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018 02; 93(2):277-285.
Score: 0.040
-
Myeloid/lymphoid neoplasms with FGFR1 rearrangement. Leuk Lymphoma. 2018 07; 59(7):1672-1676.
Score: 0.040
-
Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017 03 09; 129(10):1275-1283.
Score: 0.038
-
Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features. Am J Clin Pathol. 2016 03; 145(3):418-27.
Score: 0.036
-
Clinical validation of a multipurpose assay for detection and genotyping of CALR mutations in myeloproliferative neoplasms. Am J Clin Pathol. 2015 Nov; 144(5):746-55.
Score: 0.035
-
Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood. 2015 May 21; 125(21):3360-3.
Score: 0.034
-
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014 Apr 24; 123(17):2645-51.
Score: 0.031
-
Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):155-162.e1.
Score: 0.030
-
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013 Dec; 88(12):1024-9.
Score: 0.030
-
Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples. Genet Test Mol Biomarkers. 2013 May; 17(5):429-37.
Score: 0.029
-
Competing cell clones in myeloproliferative neoplasm. Blood. 2010 Dec 02; 116(23):5074-5.
Score: 0.025
-
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009 Nov 10; 27(32):5418-24.
Score: 0.023
-
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood. 2009 Sep 10; 114(11):2232-5.
Score: 0.022
-
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res. 2009 Nov; 33(11):1481-4.
Score: 0.022
-
Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leuk Res. 2009 Jun; 33(6):837-9.
Score: 0.021
-
Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow. Mod Pathol. 2009 Jan; 22(1):50-7.
Score: 0.021
-
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005 May 01; 11(9):3425-32.
Score: 0.017
-
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood. 2004 Oct 01; 104(7):1979-88.
Score: 0.016